Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | LSS | P48449 | 2/20 | 0.54 |
| ▸ | RARB | P10826 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10592808 | 0.94 | GAA (0.70) | GAAPPARALSSL3MBTL1PSMB1 | |
| SCHEMBL1816349 | 0.88 | GAA (0.85) | GAAPPARALSSL3MBTL1PSMB1 | |
| SCHEMBL5396195 | 0.87 | GAA (0.83) | GAAPPARALSSL3MBTL1MAPT | |
| SCHEMBL29102525 | 0.87 | GAA (0.66) | GAAPPARALSSRARBL3MBTL1 | |
| SCHEMBL8660388 | 0.86 | ALDH1A1 (0.56) | GAALSSRARBL3MBTL1NR1I2 | |
| SCHEMBL2719251 | 0.86 | ALDH1A1 (0.56) | GAALSSRARBL3MBTL1NR1I2 | |
| SCHEMBL13299419 | 0.86 | GAA (0.60) | GAAPPARALSSL3MBTL1LMNA | |
| SCHEMBL29102522 | 0.86 | GAA (0.87) | GAAPPARARARBL3MBTL1MAPT | |
| SCHEMBL14901527 | 0.84 | GAA (0.72) | GAAPPARALSSRARBL3MBTL1 | |
| SCHEMBL21889396 | 0.83 | HTT (0.62) | GAAPPARALSSRARBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954183-B2 | Curable composition, semi-cured product, cured product, optical member, lens, and compound | FUJIFILM CORPORATION (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20200115316-A1 | CURABLE COMPOSITION, SEMI-CURED PRODUCT, CURED PRODUCT, OPTICAL MEMBER, LENS, AND COMPOUND | FUJIFILM CORPORATION (JP) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115316-A1 | CURABLE COMPOSITION, SEMI-CURED PRODUCT, CURED PRODUCT, OPTICAL MEMBER, LENS, AND COMPOUND | CRYAA, Q6ZSR9, CRYZ | GAA 3348/4885PPARA 4350/4885LSS 361/4885 |
| US-10954183-B2 | Curable composition, semi-cured product, cured product, optical member, lens, and compound | CRYAA, Q6ZSR9, CRYZ | GAA 3348/4885PPARA 4350/4885LSS 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.